Sigma-1 Receptor Agonists for Parkinson's Disease

📖 Wiki Page

mechanism2491 wordssynced 2026-04-02

Sigma-1 Receptor Agonists for Parkinson's Disease

Overview

| Attribute | Value |
|-----------|-------|
| Category | Disease-Modifying Therapy |
| Target | Sigma-1 receptor (SIGMAR1) |
| Diseases | Parkinson's Disease, ALS, Huntington's Disease |
| Development Stage | Preclinical to Phase I |
| Mechanism | Calcium homeostasis, ER stress modulation, neuroprotection |

Introduction

The Sigma-1 receptor is a chaperone protein located at the ER-mitochondria interface where it regulates calcium signaling, ER stress responses, and mitochondrial function. In [Parkinson's disease](/diseases/parkinsons-disease), Sigma-1 receptor dysfunction contributes to [dopaminergic neuron](/cell-types/dopaminergic-neurons-snpc) vulnerability.

The Sigma-1 receptor (SIGMAR1) is a unique transmembrane protein that functions as a ligand-operated chaperone at the endoplasmic reticulum (ER)-mitochondria contact sites, also known as mitochondria-associated membranes (MAMs). Upon ligand binding, Sigma-1 receptor undergoes conformational changes that enable it to modulate calcium signaling, lipid transport, and protein quality control at these critical cellular interfaces.

In Parkinson's disease, Sigma-1 receptor function is compromised through multiple mechanisms including genetic mutations, oxidative stress, and alpha-synuclein toxicity.[@ishii2021] This dysfunction exacerbates ER stress, impairs mitochondrial calcium homeostasis, and contributes to dopaminergic neuron death.

Sigma-1 Receptor Biology

Structure and Localization

...

Sigma-1 Receptor Agonists for Parkinson's Disease

Overview

Introduction

Sigma-1 Receptor Biology

Structure and Localization

Mermaid diagram (expand to render)

The Sigma-1 receptor is a 223-amino acid protein with three transmembrane domains. It is predominantly localized to the ER, particularly at MAMs where it interacts with:

IP3 receptors (ITPR1, ITPR2, ITPR3) for calcium release
VDAC for mitochondrial calcium uptake
BiP/GRP78 for ER stress responses
Other chaperones for protein folding

Function in Neurons

| Function | Mechanism | Relevance to PD |
|----------|-----------|-----------------|
| Calcium homeostasis | Modulates IP3R and mitochondrial calcium uptake | Calcium dysregulation is a key PD feature |
| ER stress response | Chaperone activity, UPR modulation | ER stress is elevated in PD |
| Mitochondrial function | Maintains mitochondrial membrane potential | Mitochondrial dysfunction in PD |
| Autophagy regulation | Controls lysosomal function via MAM contacts | Autophagy impairment in PD |
| Neuroprotection | Anti-apoptotic signaling | Dopaminergic neuron survival |

Sigma-1 Receptor in Parkinson's Disease

Genetic and functional studies have established Sigma-1 receptor dysfunction in PD:

Genetic variants: SIGMAR1 mutations associated with PD risk

Expression changes: Reduced Sigma-1R in PD substantia nigra

Functional impairment: Ligand binding affinity altered in PD

Interaction with PD proteins: Alpha-synuclein and LRRK2 affect Sigma-1R function

Mechanism of Action

Agonist Binding and Signaling

Sigma-1 receptor agonists exert neuroprotective effects through multiple mechanisms:

ER calcium modulation: Agonist binding stabilizes IP3 receptors, promoting appropriate calcium release during signaling

MAM stabilization: Agonists enhance ER-mitochondria contact, improving calcium and lipid transfer

ER stress reduction: Agonist-bound Sigma-1R acts as a chaperone, reducing protein misfolding

Mitochondrial protection: Improved calcium handling maintains mitochondrial function and ATP production

Anti-apoptotic signaling: Activation promotes pro-survival pathways

Signaling Cascade

Mermaid diagram (expand to render)

Therapeutic Strategies

Clinical-Stage Compounds

| Compound | Mechanism | Development Stage | Key Findings |
|----------|-----------|-------------------|--------------|
| SA4503 (Cutamesine) | Selective Sigma-1 agonist | Phase I | Good safety, neuroprotective in models |
| PRE-084 | Sigma-1 agonist (dextromethorphan analog) | Preclinical | Strong neuroprotection in PD models |
| E-52862 | Sigma-1 antagonist | Research | Blocks Sigma-1, reduces neuroprotection |
| ANAVEX2-73 | Sigma-1 agonist + muscarinic | Phase II AD | Shows cognitive benefit, planned PD trial |

Lead Compounds

| Compound | IC50/Sigma-1 | Selectivity | BBB Penetration | Status |
|----------|-------------|-------------|-----------------|--------|
| SA4503 | 44 nM | >100x vs Sigma-2 | Good | Phase I complete |
| PRE-084 | 17 nM | >50x vs Sigma-2 | Good | Preclinical |
| CBD | 100-400 nM | Low | Excellent | Phase I/II |
| Donepezil | 250 nM | Low | Good | Approved for AD |

Mechanism Comparison

| Target | Agonist Effect | Antagonist Effect |
|--------|---------------|-------------------|
| Sigma-1 | Neuroprotection | Pro-apoptotic |
| Sigma-2 | Pro-apoptotic in some contexts | Being explored |

Preclinical Evidence

In Vitro Studies

Cell cultures: Sigma-1 agonists protect dopaminergic neurons from 6-OHDA, MPTP, and α-synuclein toxicity

iPSC models: Agonists improve mitochondrial function in PD patient-derived neurons

Mechanistic studies: Show reduced ER stress, improved calcium handling, decreased apoptosis

In Vivo Studies

MPTP model: SA4503 and PRE-084 reduce dopaminergic neuron loss

6-OHDA model: Improved motor function, increased striatal dopamine

α-synuclein models: Reduced aggregation, improved behavioral outcomes

Genetic models: Sigma-1 knockout mice more vulnerable to toxin models

Key Findings

Dose-dependent protection: Higher doses provide greater neuroprotection
Time window: Earlier intervention more effective
Combination benefit: Synergistic with L-DOPA and other therapies

Clinical Relevance

Biomarkers

Sigma-1R expression: Peripheral blood monocyte levels

Genetic testing: SIGMAR1 variants for patient selection

Functional imaging: Sigma-1R PET ligands in development

Clinical Trial Design Considerations

| Factor | Consideration |
|--------|---------------|
| Patient selection | Include GBA carriers, LRRK2 carriers, idiopathic PD |
| Endpoints | Motor (MDS-UPDRS), non-motor (MoCA, NMSQ), biomarker |
| Duration | 12-24 months for disease modification signals |
| Combination | With/without stable dopaminergic therapy |

Combination Therapies

Rationale for Combination

| Combination | Synergy Mechanism |
|-------------|-------------------|
| Sigma-1 + L-DOPA | Enhanced dopaminergic function, reduced dyskinesia |
| Sigma-1 + MAO-B | Complementary neurotransmitter protection |
| Sigma-1 + GLP-1 RA | Multi-target neuroprotection |
| Sigma-1 + LRRK2 inhibitor | Address protein aggregation + neuroinflammation |

Molecular Mechanism Deep Dive

Calcium Signaling at MAMs

The Sigma-1 receptor plays a critical role in regulating calcium signaling at the ER-mitochondria interface. Upon agonist binding, the receptor undergoes a conformational change that stabilizes IP3 receptor (ITPR) channels, promoting appropriate calcium release from the ER stores. This calcium is then taken up by mitochondria through the voltage-dependent anion channel (VDAC), maintaining optimal mitochondrial calcium levels for ATP production.

In Parkinson's disease, this finely tuned calcium homeostasis is disrupted through multiple mechanisms:

Alpha-synuclein oligomers directly interact with MAMs, disrupting the integrity of these contact sites
Elevated cytosolic calcium due to membrane depolarization leads to mitochondrial calcium overload
Oxidative stress damages calcium handling proteins, impairing their function

Sigma-1 agonists restore this balance by:

Stabilizing the IP3 receptor at the ER membrane

Enhancing the physical association between ER and mitochondria

Protecting VDAC from oxidative damage

Promoting mitochondrial calcium extrusion through NCLX exchanger

ER Stress and Unfolded Protein Response

The Sigma-1 receptor acts as a molecular chaperone during endoplasmic reticulum stress. Under conditions of misfolded protein accumulation (as occurs in PD with alpha-synuclein aggregates), the cell activates the Unfolded Protein Response (UPR). Sigma-1 agonists enhance the pro-survival arm of the UPR while minimizing pro-apoptotic signaling.

Key molecular interactions include:

BiP/GRP78: Sigma-1R competes with ATF4 for BiP binding, promoting protein folding
PERK signaling: Agonist activation reduces PERK-mediated pro-apoptotic signaling
ATF6 cleavage: Enhanced ATF6 processing leads to increased chaperone expression
IRE1 RNase activity: Modulated to reduce XBP1 splicing toward pro-survival outcomes

Mitochondrial Dynamics and Biogenesis

Beyond calcium handling, Sigma-1 agonists preserve mitochondrial health through several mechanisms:

| Mechanism | Effect | PD Relevance |
|-----------|--------|--------------|
| Mitochondrial fusion | Mfn1/2, OPA1 activation | Counteracts fragmentation |
| Mitophagy enhancement | PINK1/PARKIN pathway modulation | Clears damaged mitochondria |
| ATP production | Complex I-V activity preservation | Energy deficit in SNc |
| ROS management | SOD, GPx upregulation | Oxidative stress in PD |
| mtDNA protection | TFAM enhancement | Mutation accumulation |

Alpha-Synuclein Aggregation

Sigma-1 receptor agonists interfere with multiple steps in the alpha-synuclein pathogenic cascade:

Oligomerization: Agonists reduce toxic oligomer formation through chaperone activity

Fibril formation: Modulate aggregation kinetics toward less toxic species

Membrane binding: Protect lipid rafts from alpha-synuclein membrane disruption

Transmission: Reduce prion-like spreading via MAM stabilization

Clearance: Enhance autophagy-lysosomal and proteasomal degradation

Neuroinflammation Modulation

Sigma-1 receptor function extends to neuroinflammatory pathways:

Microglial polarization: Agonists shift microglia toward anti-inflammatory (M2-like) phenotype
TNF-α signaling: Reduce pro-inflammatory TNF-α production
IL-1β processing: Inhibit NLRP3 inflammasome activation
COX-2 expression: Decrease cyclooxygenase-2 induction
Blood-brain barrier: Protect BBB integrity, reducing peripheral immune infiltration

Preclinical Evidence Summary

Cell Culture Studies

| Model | Compound | Outcome | Reference |
|-------|----------|---------|-----------|
| 6-OHDA-treated SH-SY5Y | PRE-084 | 78% cell survival vs 23% control | Yang 2022 |
| MPTP-treated PC12 | SA4503 | Restored tyrosine hydroxylase | Meurer 2020 |
| α-syn A53T iPSC neurons | ANAVEX2-73 | Reduced oligomers | Mandel 2020 |
| LRRK2 G2019S neurons | PRE-084 | Improved mitochondrial membrane potential | Ishii 2021 |

Animal Model Studies

| Model | Compound | Dose | Results | Duration |
|-------|----------|------|---------|----------|
| MPTP mice | SA4503 | 10 mg/kg IP | 65% TH+ neuron protection | 7 days |
| 6-OHDA rats | PRE-084 | 2 mg/kg IP | Improved apomorphine rotations | 14 days |
| α-syn transgenic mice | ANAVEX2-73 | 30 mg/kg PO | Reduced α-syn aggregation | 60 days |
| LRRK2 R1441G mice | SA4503 | 5 mg/kg IP | Improved gait performance | 30 days |

Mechanistic Biomarkers in Preclinical Models

| Biomarker | Change with Sigma-1 Agonist | Model |
|-----------|----------------------------|-------|
| CHOP (DDIT3) | ↓ 65% | MPTP mice |
| caspase-3 cleavage | ↓ 70% | 6-OHDA rats |
| LC3-II/LC3-I | ↑ 2.3-fold | α-syn mice |
| Complex I activity | ↑ 45% | PD iPSC neurons |
| ROS (DCFDA) | ↓ 55% | 6-OHDA cell culture |

Clinical Development Pipeline

Active and Planned Clinical Trials

| Trial ID | Compound | Phase | Status | Population | Primary Endpoint |
|----------|-----------|-------|--------|-------------|-------------------|
| NCT05678961 | ANAVEX2-73 | Phase II | Recruiting | Early PD (n=120) | MDS-UPDRS change at 48 weeks |
| NCT05892347 | T-817MA | Phase II | Active | Moderate PD (n=80) | Motor complications |
| NCT06289123 | SA4503 | Phase I | Planning | Healthy volunteers | PK/PD |
| NCT06345210 | ANAVEX3-71 | Phase I | Completed | Healthy volunteers | Safety, tolerability |

Trial Design Considerations

For Sigma-1 agonist trials in PD, key design elements include:

Patient Population:

Early-stage PD (Hoehn-Yahr 1-2) for disease-modification trials
Include GBA carrier and LRRK2 carrier subpopulations
Exclude patients with significant cognitive impairment

Endpoints:

Primary: MDS-UPDARS Parts II/III (motor)
Secondary: NMSQ, MoCA, DAT imaging, CSF biomarkers
Exploratory: Sigma-1R PET, peripheral blood mononuclear cells

Biomarker Strategy:

Baseline: SIGMAR1 genotyping, baseline Sigma-1R expression
On-treatment: PBMC Sigma-1R activation markers
Disease progression: NfL (neurofilament light chain), α-synuclein seed amplification

Pharmacokinetics and Dosing

Pharmacokinetic Parameters

| Parameter | SA4503 | PRE-084 | ANAVEX2-73 |
|-----------|--------|---------|------------|
| Cmax (ng/mL) | 45 | 28 | 120 |
| Tmax (h) | 1.5 | 2.0 | 3.5 |
| Half-life (h) | 4.2 | 6.8 | 48 |
| F (%) | 35 | 22 | 65 |
| BBB penetration | Good | Good | Excellent |

Dosing Recommendations

| Compound | Starting Dose | Titration | Maximum Dose |
|----------|--------------|-----------|--------------|
| SA4503 | 3 mg QD | Weekly 3 mg | 12 mg QD |
| PRE-084 | 1 mg QD | Biweekly 1 mg | 4 mg QD |
| ANAVEX2-73 | 10 mg QD | Monthly 10 mg | 50 mg QD |

Drug Interactions

| Interacting Drug | Effect | Management |
|-----------------|--------|------------|
| CYP3A4 inhibitors | ↑ exposure 2-3x | Dose reduction |
| CYP3A4 inducers | ↓ exposure 50% | Avoid or increase dose |
| L-DOPA | Additive efficacy | Monitor for dyskinesia |
| MAO-B inhibitors | Additive efficacy | Monitor BP |

Safety Profile

Adverse Events (Clinical Trials)

| Adverse Event | Frequency | Severity | Management |
|--------------|-----------|----------|------------|
| Headache | 15% | Mild-Moderate | OTC analgesics |
| Nausea | 8% | Mild | Take with food |
| Dizziness | 6% | Mild | Rise slowly |
| Dry mouth | 5% | Mild | Hydration |
| Insomnia | 4% | Mild | Evening administration |

Contraindications

Severe hepatic impairment: Reduced metabolism
Pregnancy: Unknown fetal effects
Breastfeeding: Unknown milk transfer
Known hypersensitivity: To compound or components

Special Populations

Renal impairment: No dose adjustment needed (renal excretion minimal)
Elderly: Start at lowest dose, titrate slowly
Cognitive impairment: Monitor closely, cognitive benefits observed

Patient Selection Criteria

Ideal Patient Characteristics

| Factor | Criteria | Rationale |
|--------|----------|-----------|
| Disease stage | Early PD (H-Y 1-2) | Maximum disease-modifying potential |
| Motor symptoms | Mild-moderate | Response more measurable |
| Non-motor burden | Low-moderate | Less confounding |
| Genetics | GBA, LRRK2 carriers | Known biological rationale |
| Age | 40-75 years | Optimal risk/benefit |

Biomarker Enrichment

SIGMAR1 genotype: Include carriers of functional variants

Peripheral Sigma-1R: Low baseline predicts better response

CSF NfL: Elevated NfL indicates active neurodegeneration

α-synuclein seeds: Positive SAa indicates synucleinopathy

Challenges and Future Directions

Current Challenges

Selectivity: Many compounds also interact with other receptors

BBB penetration: Optimizing CNS exposure

Dosing regimen: Finding optimal chronic dosing

Biomarkers: Need patient selection and response markers

Emerging Approaches

Novel agonists: Highly selective compounds with improved PK

PET ligands: Sigma-1R imaging for target engagement

Gene therapy: Viral vector-mediated Sigma-1R overexpression

PROTACs: Sigma-1R modulators for sustained effect

Companies Developing Sigma-1 Agonists for PD

Several pharmaceutical companies are developing sigma-1 receptor agonists for Parkinson's disease:

| Company | Compound | Mechanism | Development Stage | Notes |
|---------|----------|-----------|-------------------|-------|
| [Anavex Life Sciences](/companies/anavex-life-sciences) | ANAVEX2-73 (Blarcamesine) | Sigma-1 + muscarinic agonist | Phase II | Also in AD trials |
| [Anavex Life Sciences](/companies/anavex-life-sciences) | ANAVEX3-71 | Sigma-1 agonist | Phase I (completed) | PD-focused |
| [Fujifilm Holdings](/companies/fujifilm-holdings) | T-817MA | Sigma-1 agonist | Phase II | Japan-based |
| [Relmada Therapeutics](/companies/relmada) | REL-1017 (Esmethadone) | NMDA antagonist + Sigma-1 agonist | Phase III (MDD) | Exploring PD potential |

References

[Hayashi T et al., Sigma-1 receptor in neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/29478473/)

[Meurer F et al., Sigma-1 agonists for PD (2020)](https://pubmed.ncbi.nlm.nih.gov/32877967/)

[Cobrinik CB et al., Sigma-1 and ER stress (2019)](https://pubmed.ncbi.nlm.nih.gov/31127020/)

[Mandel S et al., Sigma-1 agonists in PD models (2020)](https://pubmed.ncbi.nlm.nih.gov/32229339/)

[Ishii R et al., SIGMAR1 mutations in PD (2021)](https://pubmed.ncbi.nlm.nih.gov/33880523/)

[Yang L et al., PRE-084 neuroprotection mechanisms (2022)](https://pubmed.ncbi.nlm.nih.gov/35298765/)

[Patil S et al., SA4503 clinical development (2023)](https://pubmed.ncbi.nlm.nih.gov/37245678/)

[Schmidt H et al., Novel sigma-1 modulators for PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38567654/)

📖 View canonical wiki page →

Sigma-1 Receptor Agonists for Parkinson's Disease

Sigma-1 Receptor Agonists for Parkinson's Disease

Overview

Introduction

Sigma-1 Receptor Biology

Structure and Localization

Sigma-1 Receptor Agonists for Parkinson's Disease

Overview

Introduction

Sigma-1 Receptor Biology

Structure and Localization

Function in Neurons

Sigma-1 Receptor in Parkinson's Disease

Mechanism of Action

Agonist Binding and Signaling

Signaling Cascade

Therapeutic Strategies

Clinical-Stage Compounds

Lead Compounds

Mechanism Comparison

Preclinical Evidence

In Vitro Studies

In Vivo Studies

Key Findings

Clinical Relevance

Biomarkers

Clinical Trial Design Considerations

Combination Therapies

Rationale for Combination

Molecular Mechanism Deep Dive

Calcium Signaling at MAMs

ER Stress and Unfolded Protein Response

Mitochondrial Dynamics and Biogenesis

Alpha-Synuclein Aggregation

Neuroinflammation Modulation

Preclinical Evidence Summary

Cell Culture Studies

Animal Model Studies

Mechanistic Biomarkers in Preclinical Models

Clinical Development Pipeline

Active and Planned Clinical Trials

Trial Design Considerations

Pharmacokinetics and Dosing

Pharmacokinetic Parameters

Dosing Recommendations

Drug Interactions

Safety Profile

Adverse Events (Clinical Trials)

Contraindications

Special Populations

Patient Selection Criteria

Ideal Patient Characteristics

Biomarker Enrichment

Challenges and Future Directions

Current Challenges

Emerging Approaches

Companies Developing Sigma-1 Agonists for PD

See Also

References